Torrent Pharmaceuticals in South Africa

Torrent Pharmaceuticals Expands Footprint in South Africa Amid Strategic Growth Initiatives

Johannesburg, South Africa – July 26, 2025

Torrent Pharmaceuticals, a leading Indian pharmaceutical company, is intensifying its presence in the South African market through strategic acquisitions and partnerships. In June 2025, Torrent announced the acquisition of a controlling stake in JB Chemicals & Pharmaceuticals Ltd., a move valued at approximately ₹25,689 crore (US$3.01 billion). This acquisition is poised to bolster Torrent’s market share in India and diversify its product portfolio, particularly in chronic therapies such as cardiology and gastroenterology. (healthcaremea.com)

JB Chemicals & Pharmaceuticals Ltd. has a significant footprint in South Africa, with a strong presence in the over-the-counter (OTC) market. The acquisition is expected to enhance Torrent’s distribution capabilities and product offerings in the region. Aman Mehta, Whole-time Director of Torrent Pharmaceuticals, highlighted that the merger would not only strengthen the company’s position in chronic care but also expand its contract development and manufacturing (CDMO) capabilities, positioning it among India’s top pharmaceutical players. (businesstoday.in)

In addition to the JB Chemicals acquisition, Torrent Pharmaceuticals has been actively exploring further expansion opportunities. Reports from October 2023 indicate that the company secured commitments from a group of overseas banks to fund a potential acquisition of a 33% stake in Cipla Ltd., another major player in the pharmaceutical industry. While the deal’s valuation was not disclosed, Cipla’s market capitalization at the time was approximately $11.7 billion. This move underscores Torrent’s ambition to strengthen its position in the global pharmaceutical landscape. (business-standard.com)

Torrent Pharmaceuticals’ strategic initiatives reflect its commitment to expanding its global footprint and enhancing its product portfolio. By leveraging acquisitions and partnerships, the company aims to deliver a broader range of healthcare solutions to patients worldwide, including those in South Africa.

As Torrent Pharmaceuticals continues to grow and diversify, stakeholders in South Africa can anticipate a more robust presence of the company, potentially leading to increased access to a wider array of pharmaceutical products and services.

Torrent Pharmaceuticals’ Strategic Expansion in South Africa:

• Torrent Pharma strikes US$3B deal to acquire controlling stake in JB Chemicals | HealthCare Middle East & Africa Magazine
• Torrent lines up at least $5 billion funding to buy 33% stake in Cipla | Company News – Business Standard